We are live on ! Find out more

Teva Pharmaceutical Industries Limited

TEVA

Market cap $47.5B

40.70 USD

-1.39

3.3%

At close Updated Nov 2, 4:00 PM EST

Pre-market

After hours

40.80

+0.10

0.25%

1 day

-3.3%

5 days

2.49%

1 month

2.96%

3 months

18.11%

6 months

15.13%

Year to date

31.5%

1 year

98.34%

5 years

302.57%

10 years

-6.07%

About: Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Employees: 32,842

Healthcare Drug Manufacturers - Specialty & Generic

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 44.6%

Neutral 50.8%

Negative 4.6%

Why Is Teva Stock Trading Lower on Monday?

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), will discontinue its Phase 2 TOPAS-MSA study evaluating emrusolmin in adult patients with multiple system atrophy.

Why Is Teva Stock Trading Lower on Monday?

Teva to discontinue mid-stage neurodegenerative disorder study

Teva said on Monday it was discontinuing its mid-stage neurodegenerative disorder ‌study due to a low probability of the study meeting its main goal if continued.

Teva to discontinue mid-stage neurodegenerative disorder study

Teva: I Still See Upside After A Massive Rally

Teva Pharmaceutical Industries is undergoing a strategic transformation, pivoting from generics to innovative biopharmaceuticals, with a robust new product pipeline. FDA approval of WELTRUZA and several high-potential pipeline drugs could add $5.5B–$9B in annual peak sales, driving significant revenue growth. Financials are markedly improved: debt halved since 2017, cash balance rising, and revenue rebounding, positioning TEVA for further upside.

Teva: I Still See Upside After A Massive Rally

The Motley Fool

Teva Stock Has More Than Doubled in a Year. Where Will It Be in 3 Years?

Teva's pivot from generic drugs to branded drugs has fueled an 100% surge for shares over the past year. Based on recent results and catalysts, don't rule out a continued, steady move towards higher price levels.

Teva Stock Has More Than Doubled in a Year. Where Will It Be in 3 Years?

Zacks Investment Research

What Analyst Projections for Key Metrics Reveal About Teva Pharmaceutical Industries (TEVA) Q3 Earnings

Get a deeper insight into the potential performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

What Analyst Projections for Key Metrics Reveal About Teva Pharmaceutical Industries (TEVA) Q3 Earnings

Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline

Teva acquires worldwide rights to BXCL501, expanding its neuroscience pipeline with a potential at-home treatment for agitation currently under FDA review

Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline

Baron Health Care Fund Q3 2026 Top Contributors And Detractors

TMO's organic growth of 5% exceeded consensus by 200 basis points, and management raised full-year organic growth guidance/. MTD's local-currency sales grew 6%, exceeding prior guidance of 3%. TEVA management raised guidance for all three brands.

Baron Health Care Fund Q3 2026 Top Contributors And Detractors

Teva to Host R&D Day on Wednesday, November 11 in New York City

TEL AVIV, Israel, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will host an R&D Day on Wednesday, November 11, 2026. At the R&D Day, Teva's leadership will discuss its R&D pipeline, its near-term value-creation potential over the next five years, and Teva's ongoing transformation into an innovative biopharma company through the Pivot to Growth strategy.

Teva to Host R&D Day on Wednesday, November 11 in New York City

Zacks Investment Research

TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia

Teva wins FDA approval for Weltruza, the first once-monthly subcutaneous olanzapine injection for adults with schizophrenia, with a U.S. launch expected soon.

TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia

Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth Initiatives Transcript

Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth Initiatives Transcript

Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth Initiatives Transcript

See News Rankings

Price charts implemented using Lightweight Charts™